RNAC Stock Price, Analysis & Fundamentals | Cartesian Therapeutics, Inc.

Analysis

Cartesian Therapeutics, Inc. is a biotechnology company in the healthcare sector with 66 employees. The company has a market capitalization of $179.68 million. The financial health of Cartesian Therapeutics, Inc. is marked by significant losses. The company reported net income of -$47,979,000 and EBITDA of -$81,081,000 for the trailing twelve months. Additionally, the operating margin was -4660.6%, indicating substantial operational expenses. However, the company has a cash balance of $143.38 million to support its operations. The valuation context for Cartesian Therapeutics, Inc. is characterized by negative earnings metrics, with a forward P/E ratio of -2.68 and an EV/EBITDA ratio of -0.56. Revenue growth was 16.8% year-over-year, but the company's profitability remains uncertain due to its significant losses.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Visit website →

RNAC

Price History (1Y)

Analysis

About Cartesian Therapeutics, Inc.

Key Statistics

Company Info